GPSM2在肿瘤中作用机制的研究进展

doi:10.16352/j.issn.1001-6325.2024.10.1447

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (10): 1447-1450.doi: 10.16352/j.issn.1001-6325.2024.10.1447

GPSM2在肿瘤中作用机制的研究进展

刘林弟, 吕庆杰^*

中国医科大学附属盛京医院病理科,辽宁沈阳 110004

收稿日期:2023-11-06 修回日期:2024-04-02 出版日期:2024-10-05 发布日期:2024-09-27
通讯作者: ^* lvqjie@163.com
基金资助:
国家自然科学基金(82072095);中国医科大学附属盛京医院345人才计划

Progress of research on the mechanism of GPSM2 in tumor development

LIU Lindi, LYU Qingjie^*

Department of Pathology, Shengjing Hospital of China Medical University, Shenyang 110004,China

Received:2023-11-06 Revised:2024-04-02 Online:2024-10-05 Published:2024-09-27
Contact: ^* lvqjie@163.com

摘要/Abstract

摘要： G蛋白信号调节蛋白2(GPSM2)是一种G蛋白偶联受体信号通路的负性调节剂,在肝癌、胰腺癌、乳腺癌等中为促癌因子,在肺癌中为抑癌因子。在肿瘤细胞中,GPSM2不仅可以作用于细胞周期,影响有丝分裂,还间接作用于EGFR-AKT/ERK、PI3K/AKT、PBK/TOPK等多种信号通路,影响癌细胞增殖和迁移。GPSM2可作为多种肿瘤诊断、治疗和预后的潜在指标,有望成为肿瘤治疗新靶点。

关键词: G蛋白信号调节蛋白2, 肿瘤, 有丝分裂

Abstract: G-protein signaling modulator 2 (GPSM2) is a negative regulator of G protein coupled receptor signaling pathway, which plays an important role in cell growth. In recent years, it has been found that GPSM2 is abnormally expressed in a variety of malignant tumors and is related to many clinical symptoms of tumors. Based on the structure and function of GPSM2, this paper discusses its role and mechanism in tumor development, so as to identify new targets for tumor diagnosis and treatment.

Key words: G-protein signaling modulator 2(GPSM2), tumor, mitosis

中图分类号:

刘林弟, 吕庆杰. GPSM2在肿瘤中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(10): 1447-1450.

参考文献

[1]Mattiuzzi C, Lippi G. Current cancer epidemiology[J]. J Epidemiol Glob Health, 2019,9:217-222.
[2]Zhu J, Wen W, Zheng Z, et al. Lgn/minsc and lgn/numa complex structures suggest distinct functions in asymmetric cell division for the par3/minsc/lgn and gαi/lgn/numa pathways[J]. Mol Cell, 2011,43:418-431.
[3]McCudden CR, Willard FS, Kimple RJ, et al. G alpha selectivity and inhibitor function of the multiple goloco motif protein gpsm2/lgn[J]. Biochim Biophys Acta, 2005,1745:254-264.
[4]Rondard P, Iiri T, Srinivasan S, et al. Mutant g protein alpha subunit activated by gbeta gamma: a model for receptor activation?[J]. Proc Natl Acad Sci U S A, 2001,98:6150-6155.
[5]Yang D, Ji F, Li Y, et al. Gpsm2 serves as an independent prognostic biomarker for liver cancer survival[J]. Technol Cancer Res Treat, 2020,19:1533033820945817.doi:10.1177/1533033820945817.
[6]He XQ, Zhang YF, Yu JJ, et al. High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the pi3k/akt signaling pathway[J]. Tumour Biol, 2017,39:1010428317695971.doi: 10.1177/1010428317695971.
[7]Zhou X, Dang S, Jiang H, et al. Identification of G-protein signaling modulator 2 as a diagnostic and prognostic biomarker of pancreatic adenocarcinoma: an exploration of its regulatory mechanisms[J]. J Gastrointest Oncol, 2021,12:1164-1179.
[8]Fukukawa C, Ueda K, Nishidate T, et al. Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells[J]. Genes Chromosomes Cancer, 2010,49:861-872.
[9]Gadwal A, Purohit P, Khokhar M, et al. In silico analysis of differentially expressed-aberrantly methylated genes in breast cancer for prognostic and therapeutic targets[J]. Clin Exp Med, 2023,23:3847-3866.
[10]Dang HH, Ta HDK, Nguyen TTT, et al. Identifying gpsm family members as potential biomarkers in breast cancer: a comprehensive bioinformatics analysis[J]. Biomedicines, 2021,9:1144.doi. 10.3390/biomedicines9091144.
[11]Hu LM, Ou XH, Shi SY. A comprehensive analysis of G-protein-signaling modulator 2 as a prognostic and diagnostic marker for pan-cancer[J]. Front Genet, 2022,13:984714.doi: 10.3389/fgene.2022.984714.
[12]Deng M, Liu B, Zhang Z, et al. Loss of G-protein-signaling modulator 2 accelerates proliferation of lung adenocarcinoma via EGFR signaling pathway[J]. Int J of Biochem Cell Biol, 2020,122:105716.doi: 10.1016/j.biocel.2020.105716.
[13]Chen X, Ma J, Wang X, et al. CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine[J]. Front Endocrinol, 2022,13:1106175.doi: 10.3389/fendo.2022.1106175.
[14]Deng M, Liu B, Zhang Z, et al. Knockdown of G-protein-signaling modulator 2 promotes metastasis of non-small-cell lung cancer by inducing the expression of Snail[J]. Cancer Sci, 2020,111:3210-3221.
[15]杨铠菲, 朱静格, 张洋洋, 等. 索拉菲尼诱导的细胞凋亡和自噬对hela细胞耐药性的影响[J]. 基础医学与临床, 2024,44:467-473.
[16]郑伟,张建新,谭克,等.下调G蛋白信号调控因子2表达对胰腺癌细胞化疗敏感性的影响[J].中国普通外科杂志,2018,27:321-327.
[17]Zhang Z, Li Z, Deng M, et al. Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer[J]. Oncol Rep, 2020,43:965-974.
[18]Deng M, Zhang Z, Liu B, et al. Localization of GPSM2 in the nucleus of invasive breast cancer cells indicates a poor prognosis[J]. Front Oncol, 2020,10:227.doi: 10.3389/fonc.2020.00227.
[19]张继方,吕庆杰.浆液性卵巢癌中GPSM2的表达与化疗耐药及预后的相关性[J].临床与实验病理学杂志,2020,36:1307-1312.
[20]Han MA, Maisch P, Jung JH, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer[J].Cochrane Database Syst Rev, 2021,6:CD009294.doi: 10.1002/14651858.CD009294.pub3.
[21]Krey JF, Chatterjee P, Halford J, et al. Control of stereocilia length during development of hair bundles[J]. PLoS Biology, 2023,21:e3001964. doi:10.1371/journal.pbio.3001964.
[22]De Francesco EM, Sotgia F, Clarke RB, et al. G protein-coupled receptors at the crossroad between physiologic and pathologic angiogenesis: old paradigms and emerging concepts[J]. Int J Mol Sci, 2017,18:2713.doi: 10.3390/ijms18122713.
[23]Zhou PJ, Wang X, An N, et al. Loss of Par3 promotes prostatic tumorigenesis by enhancing cell growth and changing cell division modes[J]. Oncogene, 2019,38:2192-2205.

GPSM2在肿瘤中作用机制的研究进展

Progress of research on the mechanism of GPSM2 in tumor development

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	夏雨佳, 杨振丽, 刘玉琴. 肿瘤类器官临床前转化研究及应用[J]. 基础医学与临床, 2024, 44(9): 1214-1218.
[2]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[3]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[4]	陈笑天, 陈翀, 罗云萍. MAFB对肿瘤相关巨噬细胞极化及功能的影响[J]. 基础医学与临床, 2024, 44(7): 965-973.
[5]	谭树芬, 何利平, 杨琳琳, 杨谢兰, 杨宏英, 姚明姣, 李树清. TBL与工作坊整合教学法在妇科肿瘤学临床教学中的应用[J]. 基础医学与临床, 2024, 44(7): 1054-1057.
[6]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[7]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.
[8]	王婷婷, 郭丹, 陆君阳, 徐徕, 董海涛, 林佃新, 肖毅. 结直肠神经内分泌肿瘤细胞突变类型分析[J]. 基础医学与临床, 2024, 44(4): 523-527.
[9]	王子豪, 夏小超, 李舜. 跨膜蛋白质在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 398-402.
[10]	吴玉红, 喻才元, 叶石才. NMES1基因在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 403-407.
[11]	南璐, 郭梦杰, 高雅楠, 贾红燕. 膜联蛋白A家族成员在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(3): 393-397.
[12]	陈雪, 罗添, 魏超君. 溶血磷脂酰胆碱酰基转移酶1在肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(2): 256-259.
[13]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[14]	李文超, 李祥生, 李富光, 张志永, 惠磊, 周文科. 长链非编码RNA与疾病[J]. 基础医学与临床, 2024, 44(10): 1465-1469.
[15]	林港回, 蔡炳君, 周宇. CKAP2与恶性肿瘤[J]. 基础医学与临床, 2024, 44(10): 1470-1473.